
Illumina ILMN
$ 130.32
2.65%
Quarterly report 2025-Q3
added 10-31-2025
Illumina General and Administrative Expenses 2011-2026 | ILMN
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Illumina
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.09 B | 1.61 B | 2.09 B | 941 M | - | 835 M | 794 M | 583 M | 525 M | - | 464 M | 368 M | 262 M | 220 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.09 B | 220 M | 816 M |
Quarterly General and Administrative Expenses Illumina
| 2025-Q3 | 2025-Q2 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 277 M | 234 M | 239 M | 147 M | 439 M | 462 M | 378 M | - | - | 410 M | 308 M | - | 879 M | 413 M | 374 M | - | 192 M | 177 M | 274 M | - | 189 M | 202 M | 211 M | - | 197 M | 197 M | 183 M | - | 167 M | 161 M | 171 M | - | 139 M | 148 M | 150 M | - | 137 M | 124 M | 116 M | - | 120 M | 115 M | 110 M | - | 95.6 M | 88.7 M | 85.1 M | - | 69.8 M | 68.5 M | 68 M | - | 66 M | 69.2 M | 65.7 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 879 M | 65.7 M | 208 M |
General and Administrative Expenses of other stocks in the Diagnostics research industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
46.7 M | - | -6.23 % | $ 30.6 M | ||
|
Burning Rock Biotech Limited
BNR
|
490 M | $ 19.89 | 10.93 % | $ 211 M | ||
|
Agilent Technologies
A
|
1.62 B | $ 120.39 | 2.46 % | $ 36.6 B | ||
|
Aspira Women's Health
AWH
|
7.96 M | - | -6.19 % | $ 10.5 M | ||
|
Biocept
BIOC
|
16.1 M | - | -13.05 % | $ 7.29 M | ||
|
Check-Cap Ltd.
CHEK
|
9.46 M | - | - | $ 9.42 M | ||
|
Chembio Diagnostics
CEMI
|
24.3 M | - | 0.22 % | $ 16.8 M | ||
|
CareDx, Inc
CDNA
|
108 M | $ 17.63 | 4.75 % | $ 939 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
22.3 M | - | - | $ 562 M | ||
|
DermTech
DMTK
|
43.8 M | - | -11.32 % | $ 2.94 M | ||
|
Akumin
AKU
|
2.08 M | - | -17.87 % | $ 25.9 M | ||
|
Enzo Biochem
ENZ
|
21.7 M | - | -8.98 % | $ 14.8 K | ||
|
Co-Diagnostics
CODX
|
9.06 M | $ 1.38 | -4.83 % | $ 1.84 M | ||
|
Exact Sciences Corporation
EXAS
|
889 M | - | - | $ 19.8 B | ||
|
Accelerate Diagnostics
AXDX
|
39.2 M | - | -61.36 % | $ 2.46 M | ||
|
Castle Biosciences
CSTL
|
200 M | $ 24.37 | 3.57 % | $ 677 M | ||
|
Global Cord Blood Corporation
CO
|
187 M | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
97.9 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
3.83 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
126 M | - | 0.12 % | $ 80.1 M | ||
|
Charles River Laboratories International
CRL
|
743 M | $ 179.31 | 0.54 % | $ 8.89 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
453 M | - | - | $ 10.7 B | ||
|
Interpace Biosciences
IDXG
|
9.48 M | $ 2.2 | - | $ 9.73 M | ||
|
Danaher Corporation
DHR
|
8.24 B | $ 198.61 | 1.4 % | $ 142 B | ||
|
Heska Corporation
HSKA
|
64.1 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
15.8 M | - | -20.0 % | $ 1.06 M | ||
|
Medpace Holdings
MEDP
|
198 M | $ 520.0 | 3.74 % | $ 15 B | ||
|
Fulgent Genetics
FLGT
|
88.1 M | $ 16.02 | 4.71 % | $ 484 M | ||
|
Koninklijke Philips N.V.
PHG
|
599 M | $ 29.09 | 1.89 % | $ 20 B | ||
|
Motus GI Holdings
MOTS
|
6.58 M | - | -34.28 % | $ 263 K | ||
|
Guardant Health
GH
|
211 M | $ 86.4 | 5.1 % | $ 10.8 B | ||
|
QIAGEN N.V.
QGEN
|
128 M | - | - | $ 10.6 B | ||
|
Myriad Genetics
MYGN
|
257 M | $ 4.91 | 6.97 % | $ 455 M | ||
|
Anixa Biosciences
ANIX
|
6.63 M | $ 2.88 | 1.05 % | $ 93.5 K | ||
|
Biomerica
BMRA
|
2.98 M | $ 2.1 | 0.96 % | $ 4.82 M | ||
|
Senseonics Holdings
SENS
|
52.5 M | $ 6.75 | 0.45 % | $ 282 M | ||
|
ICON Public Limited Company
ICLR
|
585 M | $ 113.06 | 2.44 % | $ 9.33 B | ||
|
NeoGenomics
NEO
|
273 M | $ 8.35 | 4.38 % | $ 1.07 B | ||
|
Laboratory Corporation of America Holdings
LH
|
2.22 B | $ 268.87 | 1.78 % | $ 22.4 B | ||
|
Celcuity
CELC
|
27.2 M | $ 120.85 | 0.37 % | $ 5.65 B | ||
|
Neogen Corporation
NEOG
|
218 M | $ 9.61 | 5.14 % | $ 2.08 B | ||
|
Lantheus Holdings
LNTH
|
275 M | $ 82.74 | 1.31 % | $ 5.58 B | ||
|
Quest Diagnostics Incorporated
DGX
|
1.97 B | $ 194.16 | 0.65 % | $ 21.6 B | ||
|
Natera
NTRA
|
589 M | $ 214.64 | 6.31 % | $ 21.1 B | ||
|
ENDRA Life Sciences
NDRA
|
3.72 M | $ 4.96 | -4.43 % | $ 3.9 M | ||
|
Invitae Corporation
NVTA
|
192 M | - | - | $ 21.2 M | ||
|
National Research Corporation
NRC
|
54.8 M | $ 17.04 | 1.34 % | $ 381 M | ||
|
Organovo Holdings
ONVO
|
7.73 M | - | -2.3 % | $ 19.4 M | ||
|
OpGen
OPGN
|
4.54 M | - | -16.95 % | $ 1.54 M |